270 related articles for article (PubMed ID: 16608420)
1. PSA-based vaccines for the treatment of prostate cancer.
Madan RA; Gulley JL; Arlen PM
Expert Rev Vaccines; 2006 Apr; 5(2):199-209. PubMed ID: 16608420
[TBL] [Abstract][Full Text] [Related]
2. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
Arlen PM; Gulley JL; Tsang KY; Schlom J
Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
[TBL] [Abstract][Full Text] [Related]
3. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
5. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
Lubaroff DM; Karan D
Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic vaccines for prostate cancer: a review of clinical data.
Arlen PM; Gulley JL
Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910
[TBL] [Abstract][Full Text] [Related]
7. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
8. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
[TBL] [Abstract][Full Text] [Related]
9. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
Roos AK; Pavlenko M; Charo J; Egevad L; Pisa P
Prostate; 2005 Feb; 62(3):217-23. PubMed ID: 15389792
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B.
Fensterle J; Bergmann B; Yone CL; Hotz C; Meyer SR; Spreng S; Goebel W; Rapp UR; Gentschev I
Cancer Gene Ther; 2008 Feb; 15(2):85-93. PubMed ID: 18084243
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
Gulley J; Chen AP; Dahut W; Arlen PM; Bastian A; Steinberg SM; Tsang K; Panicali D; Poole D; Schlom J; Michael Hamilton J
Prostate; 2002 Oct; 53(2):109-17. PubMed ID: 12242725
[TBL] [Abstract][Full Text] [Related]
13. Current immunotherapeutic strategies in prostate cancer.
Grosso JF; Drake CG
Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
[TBL] [Abstract][Full Text] [Related]
14. Immune-based therapies for prostate cancer.
McNeel DG; Malkovsky M
Immunol Lett; 2005 Jan; 96(1):3-9. PubMed ID: 15585302
[TBL] [Abstract][Full Text] [Related]
15. [Vaccine therapy of prostate cancer].
Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
[TBL] [Abstract][Full Text] [Related]
16. The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer.
Matera L
Cancer Treat Rev; 2010 Apr; 36(2):131-41. PubMed ID: 19954892
[TBL] [Abstract][Full Text] [Related]
17. [State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus].
Eymard JC; Gervais A; Jarcau R; Bernard J
Bull Cancer; 2007 Jul; 94(7 Suppl):F69-76. PubMed ID: 17845996
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccines for the treatment of prostate cancer.
Alam S; McNeel DG
Expert Rev Vaccines; 2010 Jul; 9(7):731-45. PubMed ID: 20624047
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.
Hildenbrand B; Sauer B; Kalis O; Stoll C; Freudenberg MA; Niedermann G; Giesler JM; Jüttner E; Peters JH; Häring B; Leo R; Unger C; Azemar M
Prostate; 2007 Apr; 67(5):500-8. PubMed ID: 17262804
[TBL] [Abstract][Full Text] [Related]
20. Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen.
Cavacini LA; Duval M; Eder JP; Posner MR
Clin Cancer Res; 2002 Feb; 8(2):368-73. PubMed ID: 11839651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
